NCT06686472 Evaluation of TL-925 for the Treatment of Allergic Conjunctivitis
| NCT ID | NCT06686472 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Telios Pharma, Inc. |
| Condition | Allergic Conjunctivitis |
| Study Type | INTERVENTIONAL |
| Enrollment | 66 participants |
| Start Date | 2024-10-03 |
| Primary Completion | 2024-12-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 66 participants in total. It began in 2024-10-03 with a primary completion date of 2024-12-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In this prospective, Phase 2, randomized, double-masked, vehicle controlled study, approximately 66 eligible subjects will be randomized 1:1 to receive either TL-925 or placebo as topical ophthalmic eye drops administered bilaterally. The study comprises of a screening and treatment period using the conjunctival allergen challenge model to evaluate TL-925 for the treatment of allergic conjunctivitis.
Eligibility Criteria
Inclusion Criteria: * Individuals aged 18 years or older * Female subjects of childbearing potential and their male partners must both use a highly effective contraception method during the study. * Documented history of ocular allergies and a positive skin test reaction to a seasonal (grass, ragweed, tree pollen) or perennial (cat dander, dog dander, dust mites, cockroach) allergen as confirmed by an allergic skin test conducted at Visit 1 or within the past 60 months. * Calculated best-corrected visual activity of 0.7 LogMAR or better * Positive bilateral CAC reaction Exclusion Criteria: * Any systemic or ocular disease currently producing ocular redness and/or ocular discomfort, or that may interfere with the conduct of the study. * Any ocular surgical intervention within the last 3 months OR refractive surgery within the last 6 months * Any ongoing ocular infection (bacterial, viral or fungal)
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06686472 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Allergic Conjunctivitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06686472 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06686472 currently recruiting?
Yes, NCT06686472 is actively recruiting participants. Contact the research team at jmei@teliospharma.com for enrollment information.
Where is the NCT06686472 trial being conducted?
This trial is being conducted at Memphis, United States.
Who is sponsoring the NCT06686472 clinical trial?
NCT06686472 is sponsored by Telios Pharma, Inc.. The trial plans to enroll 66 participants.